Early intervention strategies for lung cancer detection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and cost-effectiveness of low-dose CT (LDCT) screening for lung cancer in community health service centers in Guangzhou. It employs a single-arm cluster randomized design, utilizing a digital health platform and AI technology to enhance the screening process. Participants aged 40-75, without a history of lung cancer, will be screened for early-stage lung cancer, with data collected through a dedicated mini-program. The study aims to improve early detection rates and assess the economic impact of the screening intervention.

Why it matters

Who can join: the full rules

1.Community Health Service Centers (Cluster Level)

1. Inclusion Criteria The community health service center must be located within one of the 11 districts of Guangzhou.

   The center must manage a population of over 10,000 elderly individuals. The center should be equipped with at least one CT machine and have qualified medical personnel, such as radiologists, radiologic technicians, and nursing staff.
2. Exclusion Criteria Community health centers currently participating in other public health projects or studies that may affect screening results.

Community health service centers where researchers cannot collect data or conduct follow-up.

2\. Screening Subjects (Individual Level)

1. Inclusion Criteria Aged 40-75 years. Residing in the community participating in the study for a long time. No known history of lung cancer and has not undergone lung cancer screening in the past three months.

   Able to understand and willing to sign the informed consent form, and able to participate in long-term follow-up.
2. Exclusion Criteria Individuals diagnosed with lung cancer. Individuals with severe other health issues that make them unsuitable for CT imaging.

Individuals unable to understand the study protocol or who cannot provide informed consent due to cognitive impairments.

Individuals participating in other clinical trials that may affect the results of this study.

Individuals unable to undergo follow-up.

Where it's running

• Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Jianxing He, MD — Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College
• Study coordinator: Jianxing He, MD
• Email: drjianxing.he@gmail.com
• Phone: 86-20-83337792

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab guided by ctDNA levels (PALACE)

  This study will see if starting adults with advanced (stage IIIB/C or IV) non-small cell lung cancer and PD-L1 ≥50% on cemiplimab, then using ctDNA and early scans to decide whether to add chemotherapy, can improve overall survival.

  Recruiting at 19 sites Phase 2 Fundación GECP · Alicante, Alicante and 19 other locations · NCT06917573

• Teniposide after prior therapy for c-Myc–driven extensive-stage small cell lung cancer

  This will try teniposide in people with extensive-stage small cell lung cancer driven by high c-Myc who have progressed after standard treatment.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT06758700

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Tarlatamab as maintenance treatment after chemo-radiotherapy for limited-stage small-cell lung cancer.

  This trial will test whether giving tarlatamab after chemo-radiotherapy helps people with limited-stage small-cell lung cancer stay progression-free longer.

  Recruiting at 20 sites Phase 2 Fundación GECP · Albacete, Albacete and 19 other locations · NCT07242547

• High-sensitivity blood test to detect and monitor multiple cancers

  This study will test a high-sensitivity blood test that looks for tumor DNA to detect and follow several common cancers in adults with those cancers or people having routine health screenings.

  Recruiting Yonsei University · Seoul · NCT07035587

• Trop2- and EpCAM-targeted PET/CT to help distinguish non-small cell lung cancer

  This project will test whether PET/CT scans that target Trop2 and EpCAM can show protein expression in tumors of people with suspected non-small cell lung cancer.

  Recruiting RenJi Hospital · Shanghai · NCT07026110

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.